ArticleOncology letters2024

Safety and efficacy of pyrotinib for HER‑2‑positive breast cancer in the neoadjuvant setting: A systematic review and meta‑analysis.

Qian Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.